Sara K Tedeschi1, Tristan Pascart2, Augustin Latourte3, Cattleya Godsave4, Burak Kundakci4, Raymond P Naden, William J Taylor5, Nicola Dalbeth6, Tuhina Neogi7, Fernando Perez-Ruiz8, Ann Rosenthal9, Fabio Becce10, Eliseo Pascual11, Mariano Andres11, Thomas Bardin3, Michael Doherty4, Hang-Korng Ea3, Georgios Filippou12, John FitzGerald13, Marwin Guitierrez14, Annamaria Iagnocco15, Tim L Jansen16, Minna J Kohler17, Frédéric Lioté3, Mark Matza17, Geraldine M McCarthy18, Roberta Ramonda19, Anthony M Reginato20, Pascal Richette3, Jasvinder A Singh21, Francisca Sivera22, Alexander So10, Lisa K Stamp23, Janeth Yinh17, Chio Yokose17, Robert Terkeltaub24, Hyon Choi17, Abhishek Abhishek4. 1. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Lille Catholic University, Lille, France. 3. Hôpital Lariboisière, Université de Paris, Paris, France. 4. University of Nottingham, Nottingham, UK. 5. University of Otago, Wellington, New Zealand. 6. University of Auckland, Auckland, New Zealand. 7. Boston University School of Medicine, Boston, Massachusetts. 8. Osakidetza, Ezkerraldea-Enkarterri-Cruces, Cruces University Hospital, Biocruces-Bizkaia Health Research Institute, and University of the Basque Country, Spain. 9. Medical College of Wisconsin, Milwaukee. 10. Lausanne University Hospital, Lausanne, Switzerland. 11. Hospital General Universitario de Alicante and Alicante Institute of Sanitary and Biomedical Research, Alicante, Spain. 12. Luigi Sacco University Hospital, Milan, Italy. 13. David Geffen School of Medicine, University of California, Los Angeles. 14. Instituto Nacional de Rehabilitación, Mexico City, Mexico. 15. Università degli Studi di Torino, Turin, Italy. 16. VieCuri Medical Center, Venlo, Noord-Limburg, and University of Twente, Enschede, The Netherlands. 17. Massachusetts General Hospital and Harvard Medical School, Boston. 18. Mater Misericordiae University Hospital, Dublin, Ireland. 19. University of Padova, Padova, Italy. 20. Brown University, Providence, Rhode Island. 21. University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center. 22. Hospital General Universitario Elda, Elda, and Universidad Miguel Hernandez, Elche, Spain. 23. University of Otago, Christchurch, New Zealand. 24. San Diego Veterans Administration Healthcare Service and University of California-San Diego.
Abstract
OBJECTIVE: Classification criteria for calcium pyrophosphate deposition (CPPD) disease will facilitate clinical research on this common crystalline arthritis. Our objective was to report on the first 2 phases of a 4-phase process for developing CPPD classification criteria. METHODS: CPPD classification criteria development is overseen by a 12-member steering committee. Item generation (phase I) included a scoping literature review of 5 literature databases and contributions from a 35-member combined expert committee and 2 patient research partners. Item reduction and refinement (phase II) involved a combined expert committee meeting, discussions among clinical, imaging, and laboratory advisory groups, and an item-rating exercise to assess the influence of individual items toward classification. The steering committee reviewed the modal rating score for each item (range -3 [strongly pushes away from CPPD] to +3 [strongly pushes toward CPPD]) to determine items to retain for future phases of criteria development. RESULTS: Item generation yielded 420 items (312 from the literature, 108 from experts/patients). The advisory groups eliminated items that they agreed were unlikely to distinguish between CPPD and other forms of arthritis, yielding 127 items for the item-rating exercise. Fifty-six items, most of which had a modal rating of +/- 2 or 3, were retained for future phases. As numerous imaging items were rated +3, the steering committee recommended focusing on imaging of the knee and wrist and 1 additional affected joint for calcification suggestive of CPP crystal deposition. CONCLUSION: A data- and expert-driven process is underway to develop CPPD classification criteria. Candidate items comprise clinical, imaging, and laboratory features.
OBJECTIVE: Classification criteria for calcium pyrophosphate deposition (CPPD) disease will facilitate clinical research on this common crystalline arthritis. Our objective was to report on the first 2 phases of a 4-phase process for developing CPPD classification criteria. METHODS: CPPD classification criteria development is overseen by a 12-member steering committee. Item generation (phase I) included a scoping literature review of 5 literature databases and contributions from a 35-member combined expert committee and 2 patient research partners. Item reduction and refinement (phase II) involved a combined expert committee meeting, discussions among clinical, imaging, and laboratory advisory groups, and an item-rating exercise to assess the influence of individual items toward classification. The steering committee reviewed the modal rating score for each item (range -3 [strongly pushes away from CPPD] to +3 [strongly pushes toward CPPD]) to determine items to retain for future phases of criteria development. RESULTS: Item generation yielded 420 items (312 from the literature, 108 from experts/patients). The advisory groups eliminated items that they agreed were unlikely to distinguish between CPPD and other forms of arthritis, yielding 127 items for the item-rating exercise. Fifty-six items, most of which had a modal rating of +/- 2 or 3, were retained for future phases. As numerous imaging items were rated +3, the steering committee recommended focusing on imaging of the knee and wrist and 1 additional affected joint for calcification suggestive of CPP crystal deposition. CONCLUSION: A data- and expert-driven process is underway to develop CPPD classification criteria. Candidate items comprise clinical, imaging, and laboratory features.
Authors: G Filippou; A Adinolfi; A Iagnocco; E Filippucci; M A Cimmino; I Bertoldi; V Di Sabatino; V Picerno; A Delle Sedie; L M Sconfienza; B Frediani; C A Scirè Journal: Osteoarthritis Cartilage Date: 2016-01-27 Impact factor: 6.576
Authors: Jasvinder A Singh; Daniel H Solomon; Maxime Dougados; David Felson; Gillian Hawker; Patricia Katz; Hal Paulus; Carol Wallace Journal: Arthritis Rheum Date: 2006-06-15
Authors: Jaap Fransen; Sindhu R Johnson; Frank van den Hoogen; Murray Baron; Yannick Allanore; Patricia E Carreira; László Czirják; Christopher P Denton; Oliver Distler; Daniel E Furst; Armando Gabrielli; Ariane Herrick; Murat Inanc; Bashar Kahaleh; Otylia Kowal-Bielecka; Thomas A Medsger; Ulf Mueller-Ladner; Gabriela Riemekasten; Stanislaw Sierakowski; Gabriele Valentini; Doug Veale; Madelon C Vonk; Ulrich Walker; Lorinda Chung; Philip J Clements; David H Collier; Mary E Csuka; Sergio Jimenez; Peter A Merkel; James R Seibold; Richard Silver; Virginia Steen; Alan Tyndall; Marco Matucci-Cerinic; Janet E Pope; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2012-03 Impact factor: 4.794
Authors: E Cipolletta; G Filippou; C A Scirè; A Di Matteo; J Di Battista; F Salaffi; W Grassi; E Filippucci Journal: Osteoarthritis Cartilage Date: 2021-02-10 Impact factor: 6.576
Authors: Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vazquez-Mellado; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor Journal: Arthritis Rheumatol Date: 2015-10 Impact factor: 10.995
Authors: Sara K Tedeschi; Fabio Becce; Tristan Pascart; Ali Guermazi; Jean-François Budzik; Nicola Dalbeth; Georgios Filippou; Annamaria Iagnocco; Minna J Kohler; Jean-Denis Laredo; Stacy E Smith; F Joseph Simeone; Janeth Yinh; Hyon Choi; Abhishek Abhishek Journal: Arthritis Care Res (Hoboken) Date: 2022-04-19 Impact factor: 5.178